![]() |
UMIN-CTR Clinical Trial |
|
![]() |
![]() |
![]() |
![]() |
Name: | UMIN ID: |
Recruitment status | No longer recruiting |
Unique ID issued by UMIN | UMIN000040330 |
Receipt No. | R000046018 |
Scientific Title | Prospective evaluation for Propofol sedation in screening endoscopy |
Date of disclosure of the study information | 2020/05/08 |
Last modified on | 2020/05/08 |
Basic information | ||
Public title | Prospective evaluation for Propofol sedation in screening endoscopy | |
Acronym | Propofol evaluation | |
Scientific Title | Prospective evaluation for Propofol sedation in screening endoscopy | |
Scientific Title:Acronym | Propofol evaluation | |
Region |
|
Condition | ||
Condition | Healthy people | |
Classification by specialty |
|
|
Classification by malignancy | Others | |
Genomic information | NO |
Objectives | |
Narrative objectives1 | Propofol has expectedly been a good drug for sedation. In an outpatient setting, safety and satisfaction of propofol sedation have not been fully evaluated. |
Basic objectives2 | Safety |
Basic objectives -Others | |
Trial characteristics_1 | |
Trial characteristics_2 | |
Developmental phase |
Assessment | |
Primary outcomes | Safety of propofol sedation |
Key secondary outcomes |
Base | |
Study type | Observational |
Study design | |
Basic design | |
Randomization | |
Randomization unit | |
Blinding | |
Control | |
Stratification | |
Dynamic allocation | |
Institution consideration | |
Blocking | |
Concealment |
Intervention | |
No. of arms | |
Purpose of intervention | |
Type of intervention | |
Interventions/Control_1 | |
Interventions/Control_2 | |
Interventions/Control_3 | |
Interventions/Control_4 | |
Interventions/Control_5 | |
Interventions/Control_6 | |
Interventions/Control_7 | |
Interventions/Control_8 | |
Interventions/Control_9 | |
Interventions/Control_10 |
Eligibility | ||||
Age-lower limit |
|
|||
Age-upper limit |
|
|||
Gender | Male and Female | |||
Key inclusion criteria | screening endoscopy using propofol | |||
Key exclusion criteria | no written consent | |||
Target sample size | 2300 |
Research contact person | |||||||
Name of lead principal investigator |
|
||||||
Organization | Sendai City Medical Center | ||||||
Division name | Department of Gastroenterology | ||||||
Zip code | 983-0824 | ||||||
Address | 5-22-1, Tsurugaya, Miyagino-ku | ||||||
TEL | 022-252-1111 | ||||||
yoshi-hk@openhp.or.jp |
Public contact | |||||||
Name of contact person |
|
||||||
Organization | Sendai City Medical Center | ||||||
Division name | Department of Gastroenterology | ||||||
Zip code | 983-0824 | ||||||
Address | 5-22-1, Tsurugaya, Miyagino-ku | ||||||
TEL | 022-252-1111 | ||||||
Homepage URL | |||||||
yoshi-hk@openhp.or.jp |
Sponsor | |
Institute | Sendai City Medical Center |
Institute | |
Department |
Funding Source | |
Organization | Self-funding |
Organization | |
Division | |
Category of Funding Organization | Self funding |
Nationality of Funding Organization |
Other related organizations | |
Co-sponsor | |
Name of secondary funder(s) |
IRB Contact (For public release) | |
Organization | Sendai City Medical Center |
Address | 5-22-1, Tsurugaya, Miyagino-ku |
Tel | 022-252-1111 |
yoshihk44@yahoo.co.jp |
Secondary IDs | |
Secondary IDs | NO |
Study ID_1 | |
Org. issuing International ID_1 | |
Study ID_2 | |
Org. issuing International ID_2 | |
IND to MHLW |
Institutions | |
Institutions |
Other administrative information | |||||||
Date of disclosure of the study information |
|
Related information | |
URL releasing protocol | Here |
Publication of results | Unpublished |
Result | |||||||
URL related to results and publications | Here | ||||||
Number of participants that the trial has enrolled | 2305 | ||||||
Results | Of 2305 eligible participants, no severe adverse effects nor accidents were reported.
Eighty-six percent of the participants replied to hope to receive similar sedation in future endoscopy. |
||||||
Results date posted |
|
||||||
Results Delayed | |||||||
Results Delay Reason | |||||||
Date of the first journal publication of results | |||||||
Baseline Characteristics | mean age, 64 year
male, 1215 |
||||||
Participant flow | Among 17989 endoscopy examinations during the study period, 4122 examinees underwent propofol administration.
Of 3166 eligible people, 2305 participated in the study. |
||||||
Adverse events | mild SpO2 decrease in 2.6% and mile HR decrease in 0.09% | ||||||
Outcome measures | No severe adverse effects were observed | ||||||
Plan to share IPD | None | ||||||
IPD sharing Plan description | None |
Progress | |||||||
Recruitment status | No longer recruiting | ||||||
Date of protocol fixation |
|
||||||
Date of IRB |
|
||||||
Anticipated trial start date |
|
||||||
Last follow-up date |
|
||||||
Date of closure to data entry |
|
||||||
Date trial data considered complete |
|
||||||
Date analysis concluded |
|
Other | |
Other related information | Observation was conducted using a questionnaire survey |
Management information | |||||||
Registered date |
|
||||||
Last modified on |
|
Link to view the page | |
URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046018 |
Research Plan | |
Registered date | File name |
Research case data specifications | |
Registered date | File name |
Research case data | |
Registered date | File name |